Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Antithrombotic Therapy After TAVI: Evidence, Discordance, and Clinical Implications

Author(s): Felice Gragnano, Arturo Cesaro and Paolo Calabrò*

Volume 20, Issue 4, 2022

Published on: 08 June, 2022

Page: [318 - 320] Pages: 3

DOI: 10.2174/1570161120666220413094635

« Previous Next »
[1]
Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group. ESC/EACTS Scientific document group, ESC scientific document group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43(7): 561-632.
[http://dx.doi.org/10.1093/eurheartj/ehab395]
[2]
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the american college of Cardiology/American heart association joint committee on clinical practice guidelines. Circulation 2021; 143(5): e72-e227.
[http://dx.doi.org/10.1161/CIR.0000000000000923] [PMID: 33332150]
[3]
Calabrò P, Gragnano F, Niccoli G, et al. Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease. Circulation 2021; 144(16): 1323-43.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.121.054305] [PMID: 34662163]
[4]
Leonardi S, Gragnano F, Carrara G, et al. Prognostic implications of declining hemoglobin content in patients hospitalized with acute coronary syndromes. J Am Coll Cardiol 2021; 77(4): 375-88.
[http://dx.doi.org/10.1016/j.jacc.2020.11.046] [PMID: 33509394]
[5]
Gragnano F, Spirito A, Corpataux N, et al. Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. EuroIntervention 2021; 17(11): e898-909.
[http://dx.doi.org/10.4244/EIJ-D-21-00181] [PMID: 34105513]
[6]
Gragnano F, Heg D, Franzone A, et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: Insights from the GLOBAL LEADERS and GLASSY. Eur Heart J Cardiovasc Pharmacother 2022; 8(1): 28-38.
[http://dx.doi.org/10.1093/ehjcvp/pvaa106] [PMID: 32941620]
[7]
Gragnano F, Calabrò P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? Eur Heart J 2019; 40(2): 216-7.
[http://dx.doi.org/10.1093/eurheartj/ehy675] [PMID: 30395219]
[8]
Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020; 383(15): 1447-57.
[http://dx.doi.org/10.1056/NEJMoa2017815] [PMID: 32865376]
[9]
Ten Berg J, Sibbing D, Rocca B, et al. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: A consensus document of the ESC working group on Thrombosis and the European Association of Percutaneous Cardiovascular interventions (EAPCI), in collaboration with the ESC council on valvular heart disease. Eur Heart J 2021; 42(23): 2265-9.
[http://dx.doi.org/10.1093/eurheartj/ehab196] [PMID: 33822924]
[10]
Valgimigli M, Gragnano F, Branca M, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: Individual patient level meta-analysis of randomised controlled trials. BMJ 2021; 373(1332): n1332.
[http://dx.doi.org/10.1136/bmj.n1332] [PMID: 34135011]
[11]
Cesaro A, Gragnano F, Calabrò P, et al. START-ANTIPLATELET collaborators. Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. Int J Cardiol 2021; 345: 7-13.
[http://dx.doi.org/10.1016/j.ijcard.2021.10.138] [PMID: 34695525]
[12]
Dangas GD, Tijssen JGP, Wöhrle J, et al. GALILEO Investigators. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med 2020; 382(2): 120-9.
[http://dx.doi.org/10.1056/NEJMoa1911425] [PMID: 31733180]
[13]
Collet JP. Anti-thrombotic strategy to lower all cardiovascular and neurologic ischemic and hemorrhagic events after trans-aortic valve implantation for aortic stenosis - ATLANTIS. American College of Cardiology (ACC) Virtual Annual Scientific Session Available from: clinicaltrial.govNVT02664649.
[14]
Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020; 382(18): 1696-707.
[http://dx.doi.org/10.1056/NEJMoa1915152] [PMID: 32223116]
[15]
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. ENVISAGE-TAVI AF Investigators. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med 2021; 385(23): 2150-60.
[http://dx.doi.org/10.1056/NEJMoa2111016] [PMID: 34449183]

Rights & Permissions Print Cite
Article Metrics
6
© 2024 Bentham Science Publishers | Privacy Policy